164 results about "Pancreatitides" patented technology

Invented is a method of inhibiting the activity / function of PI3 kinases using quinoline derivatives. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of quinoline derivatives.

Monoclonal antibodies are identified that bind the IL-21 protein. These antibodies are used to identify regions of the IL-21 protein to where binding neutralizes IL-21 activity. Hybridomas and methods of producing anti-IL-21 monoclonal antibodies are described. The monoclonal antibodies are useful in treating IL-21-mediated diseases, which may include autoimmune and inflammatory diseases such as pancreatitis, type I diabetes (IDDM), Graves Disease, inflammatory bowel disease (IBD), Crohn's Disease, ulcerative colitis, irritable bowel syndrome, multiple sclerosis, rheumatoid arthritis, diverticulosis, systemic lupus erythematosus, psoriasis, ankylosing spondylitis, scleroderma, systemic sclerosis, psoriatic arthritis, osteoarthritis, atopic dermatitis, vitiligo, graft vs. host disease (GVHD), cutaneous T cell lymphoma (CTCL), Sjogren's syndrome, glomerulonephritis, IgA nephropathy, graft versous host disease, transplant rejection, atopic dermatitis, anti-phospholipid syndrome, and asthma, and other autoimmune diseases.

The present invention relates to novel dihydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, obesity, oxysterol elimination in bile, pancreatitis, Parkinson's disease, a peroxisome proliferator activated receptor-associated disorder, phospholipid elimination in bile, renal disease, septicemia, metabolic syndrome disorders (e.g., Syndrome X), thrombotic disorder. Compounds and methods of the invention can also be used to modulate C reactive protein or enhance bile production in a patient. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.

Provided herein are methods and compositions comprising bile acid transport inhibitors and / or enteroendocrine peptide enhancing agents and / or FXR agonists for the treatment of pancreatitis or prevention of pancreatitis.

Compounds which are antagonists of MCP-1 function and are useful in the prevention or treatment of chronic or acute inflammatory or autoimmune diseases, especially those associated with aberrant lymphocyte or monocyte accumulation such as arthritis, asthma, atherosclerosis, diabetic nephropathy, inflammatory bowel disease, Crohn's disease, multiple sclerosis, nephrtitis, pancreatitis, pulmonary fibrosis, psoriasis, restenosis, and transplant rejection; pharmaceutical compositions comprising these compounds; and the use of these compounds and compositions in the prevention or treatment of such diseases.

The present invention relates to novel cycloalkyl-hydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, obesity, oxysterol elimination in bile, pancreatitis, Parkinson's disease, a peroxisome proliferator activated receptor-associated disorder, phospholipid elimination in bile, renal disease, septicemia, Syndrome X, thrombotic disorder. Compounds and methods of the invention can also be used to modulate C reactive protein or enhance bile production in a patient. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.

The invention discloses a test card for rapidly diagnosing pancreatic trauma and acute pancreatitis and a preparation method of the test card. The test card comprises a plastic shell, a bottom lining and detection modules, wherein the plastic shell is provided with a sampling hole and an observation window, and the sampling hole and the observation window are fixed with transparent waterproof films. The bottom lining is provided with multiple longitudinally parallel arranged slots; and the number of the detection modules is consistent to that of the bottom lining, and the detection modules are glued into the slots of the bottom lining. Each detection module comprises chromatographical membranes, combination pads, sample pads, filtration pads and water sucking pads. The chromatographical membranes are provided with test lines and quality control lines, the test lines are TAP (thiamphenicol) polyclonal antibodies, and the quality control lines are covered rabbit anti-mice immune globulin antibodies. The test card for rapidly diagnosing pancreatic trauma provided by the invention is capable of quickly and accurately diagnosing the diseases such as pancreatic trauma and acute pancreatitis, and adding multiple samples simultaneously for positive control and negative control, and has the advantages of being convenient and rapid to detect, high in flexibility and accuracy, stable in property and cheap in cost.

Compositions of the present invention, comprising the combination of enterically coated and uncoated pancreatic enzyme-containing beads are useful for treating or preventing pancreatitis pain, and optionally disorders associated with digestive enzyme deficiencies.

A compound of formula (I) wherein R<1> and R<2> are as defined in the description, R<2> being an aromatic group, useful in the treatment and condition selected from the group consisting of the group meningitis and salpingitis, septic shock, disseminated intravascular coagulation, and / or adult respiratory distress syndrome, acute or chronic inflammation, arthritis, cholangitis, colitis, encephalitis, endocarditis, glomerulonephritis, hepatitis, myocarditis, pancreatitis, pericarditis, reperfusion injury, vasculitis, acute and delayed hypersensitivity, graft rejection, and graft-versus-host disease, auto-immune diseases including Type 1 diabetes mellitus and multiple sclerosis, periodonate diseases, interstitial pulmonary fibrosis, cirrhosis, systemic sclerosis, keloid formation tumors which produce IL-1 as an autocrine growth factor, cachexia, Alzeimer's disease, percussion injury, depression, atherosclerosis, osteoporosis in a mammal, including a human.

The present invention relates to a urea derivative of the formula (1)wherein each symbol is as described in the specification, a pharmaceutically acceptable salt thereof and pharmaceutical use thereof. The compound of the present invention has a C5a receptor antagonistic action and is useful as an agent for the prophylaxis or treatment of diseases or syndromes due to inflammation caused by C5a [e.g., autoimmune diseases such as rheumatism, systemic lupus erythematosus and the like, sepsis, adult respiratory distress syndrome, chronic obstructive pulmonary disease, allergic diseases such as asthma and the like, atherosclerosis, cardiac infarction, brain infarction, psoriasis, Alzheimer's disease and serious organ injury (e.g., pneumonia, nephritis, hepatitis, pancreatitis and the like) due to activation of leukocytes caused by ischemia, trauma, burn, surgical invasion and the like]. In addition, it is useful as an agent for the prophylaxis or treatment of infectious diseases caused by bacteria or virus that invades via a C5a receptor.

The invention discloses a prediction model for organ failure induced by acute pancreatitis, and the model comprises the following steps: S100, preprocessing patient information, and recording events and time nodes by means of {Variables, Time}; s200, sorting the events according to a time sequence, and filling missing values by adopting a Decay mechanism; and S300, carrying out one-hot coding on the data by using an Embedded mechanism, mapping the data to a real vector space, normalizing the data and then inputting the normalized data into a Phased LSTM model. Time gate output is calculated according to the interval time of a patient from admission to the time node of the event, the model training process is accelerated by utilizing the output result of the time gate, the neuron of the output layer is 2, and a softmax function is adopted as an activation function. According to the method, heterogeneous multi-dimensional data can be processed, time information can be flexibly used, andmeanwhile, the judgment of the model is closer to a description of a disease natural process in the real world.

The present invention provides a compound emodin baicalein injection for curing acute pancreatitis and its preparation method. Said invention adopts the combination of ultrasonic wave method and conventional method to respectively extract effective component emodin and baicalein pure products from rhubarb and scutellaria root, then adopts the following steps: adding the emodin and baicalein pure products and required correspondent auxiliary material into hot injection water, using NaOH solution to regulate pH, adding active carbon, heating to foiling, cooling and filtering by using microporous filtration membrane, adding injection water to total quantity, filling and sterilizing for 30 min at 115 deg.C so as to obtain the injection, cold-storing said injection for 1 week, filtering, filling and freeze-drying, sealing so as to obtain the freeze-dried powder injection finished product.

The invention relates to emodin solid dispersion, a drug-containing pellet core, a colonic targeted micropill, and applications of the three. The emodin solid dispersion is prepared from emodin and a carrier material, wherein the carrier material is one or several selected from poloxamer 188, poloxamer 407, Kollidon 12 PF, Kollidon VA 64, Kollicoat IR or Soluplus, and the weight ratio of emodin to the carrier material is 1:2-1:15. The drug-containing pellet core and the colonic targeted micropill both contain the emodin solid dispersion. The emodin solid dispersion is substantially improved in solubility of indissolvable drug emodin; and the targeted micropill helps to realize colonic positioning release in vivo / vitro of emodin, and has substantial protective effect on intestinal barrier of a rat severe acute pancreatitis pancreatitis model.

The invention discloses Yidanshu capsules, a preparation method thereof and a quality standard. The preparation method comprises the following steps: oyster shell is decocted by adding 6-10 times the weight of water, and the filtration is carried out; the residues of the oyster shell, turmeric, Mongolian dandelion herb, red paeony root, yanhusuo and Chinese thorowax root are decocted by two times by adding 8-12 times the weight of the water respectively, and decocted liquid is filtered; rhubarb is decocted by two times by adding 6-10 times the weight of the water respectively, and the decocted liquid is filtered; filtrate is merged and vacuum concentrated to a thick paste, and the drying, the smashing and the packaging into capsules are carried out. The Yidanshu capsules adopt the advanced ceramic membrane filtration technology to remove a large number of impurities, thereby being characterized by refining, high efficiency, convenient administration, etc. The invention further establishes the quality standard of the Yidanshu capsules, the quality standard is proved to have a certain exclusivity, accuracy, reproducibility and practicality through the methodology study and the quality standard can effectively control the intrinsic quality changes of products. The quality standard is greatly improved on the basis of the original standard, thereby ensuring safety, effectiveness and controllability of drug.

Compositions and methods related to the amelioration of pancreatitis through the pharmaceutical manipulation of calcium signaling are disclosed. Such compositions and methods may be used to ameliorate symptoms of acute or chronic pancreatitis or to reduce the chance or severity of pancreatitis in an individual at risk of the condition. In other embodiments, disclosed herein are compositions and methods related to the amelioration of viral diseases through the pharmaceutical manipulation of calcium signaling. In further embodiments, disclosed herein are compositions and methods related to the amelioration of Th17-induced diseases through the pharmaceutical manipulation of calcium signaling.

Compositions of the present invention, comprising the combination of enterically coated and uncoated pancreatic enzyme-containing beads are useful for treating or preventing pancreatitis pain, and optionally disorders associated with digestive enzyme deficiencies.

Invented is a method of inhibiting the activity / function of PI3 kinases using thiazolidinedione derivatives. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of thiazolidinedione derivatives.

This invention relates generally to neuropeptide Y (“NPY”) Y4 receptor agonists including pancreatic polypeptide (PP), analogs thereof, and peptide fragments of PP, e.g. PP(32-36), and analogs thereof to pharmaceutical compositions containing such Y4 receptor agonists, and to methods for treatment of mammals using the same. The NPY Y4 receptor agonists may be administered to mammals either alone or in combination with NPY Y2 receptor agonists including peptide (PYY) (3-36), analogs thereof and to peptide fragments of PYY(3-36), e.g. PYY(22-36) and PYY(25-36), and analogs thereof such as to control food intake in mammals, blood pressure, cardiovascular response, libido, circadian rhythm, hyperlipidimia, chronic pancreatitis, and nonalcoholic fatty liver disease including nonalcoholic steatohepatitis.

Compositions and methods related to the amelioration of pancreatitis through the pharmaceutical manipulation of calcium signaling are disclosed. Such compositions and methods may be used to ameliorate symptoms of acute or chronic pancreatitis or to reduce the chance or severity of pancreatitis in an individual at risk of the condition. In other embodiments, disclosed herein are compositions and methods related to the amelioration of viral diseases through the pharmaceutical manipulation of calcium signaling. In further embodiments, disclosed herein are compositions and methods related to the amelioration of Th17-induced diseases through the pharmaceutical manipulation of calcium signaling.

The invention discloses a pancreatitis necrosis lesion debridement drainage instrument. The instrument comprises an arc seat, a mounting hole is formed in the side wall of the arc seat; a flow guide pipe is connected into the mounting hole in a sealing manner; the flow guide pipe penetrates through the mounting hole; a first drainage tube and a second drainage tube are respectively connected to two ends of the flow guide pipe in a sealing manner; a negative pressure pump is arranged at one end of the first drainage tube, two arc-shaped grooves are formed in the side wall, close to the second drainage tube, of the arcd base, the two arc-shaped grooves are located in the two sides of the second drainage tube respectively, medical adhesive tapes are arranged in the two arc-shaped grooves, andone end of the second drainage tube is connected with a mounting cylinder in a sealed mode. According to the debridement instrument, debridement liquid can be rapidly extracted from the body, in theextraction process, outside bacteria are prevented from entering the body, the health of a patient is guaranteed, after extraction is completed, the arc-shaped cover plate can be covered, repeated suturing is avoided, after the cover plate is covered, bacteria can be prevented from entering the body, and the health of the patient is protected.

The invention provides a cistanche deserticola polysaccharide extraction method which comprises the following steps: (1) extracting cistanche deserticola medicinal material coarse powder with ethyl acetate and ethanol in sequence, and collecting medicine residues to obtain degreased cistanche deserticola powder; (2) adding papain, cellulase and pectinase into degreased cistanche deserticola powder, adding water to enable the solid-liquid ratio to be 1: 20-1: 25 times, performing enzymolysis, performing ultrasonic extraction for 0.5-0.75 hour for 1-3 times, combining filtrates, centrifuging, taking a supernatant, concentrating, adding ethanol into a concentrated solution until the total concentration of the ethanol is 80 percent, and standing; centrifuging to obtain precipitate, and freeze-drying the precipitate. The invention further provides application of the cistanche polysaccharide in preparation of a medicine for preventing or treating acute alcoholic pancreatitis. The cistanche deserticola polysaccharide is extracted by using the method.

If smooth transportation of bile toward the duodenum is difficult due to cancerous cells growing in the bile duct or due to stricture of the bile duct, a cylindrical stent may be implanted into the stenosed site of the bile duct to enable smooth supply of bile. Conventional stents have no risk of slippage at an implanted position thereof, but suffer from invasively growing cancerous cells. Although a covered stent having a coating has been proposed to solve invasion of the growing cancerous cells, the covered stent may have a risk of slippage at an implanted position thereof and also, may cause pancreatitis and cholelithiasis. To solve the above described problems, disclosed herein is a stent to prevent backflow of food from the duodenum to the bile duct while assuring smooth transportation of bile without a risk of unwanted displacement caused by the transported bile. The stent includes a cylindrical outer stent, and a downwardly tapered inner stent covered with a polytetrafluoroethylene (PTFE) or silicone coating having biocompatibility. The inner and outer stents are coupled to each other to define a double structure.

The present invention provides one kind of amylopsin activity detecting solution and its use. The present invention makes it possible to realize the routine monitoring of pancreas function and the clinical detection of acute pancreatitis.

The invention discloses a severe pancreatitis prediction model construction method based on a machine learning method, and the method comprises the following steps: obtaining clinical and laboratory index related data of a prediction object, and carrying out the preprocessing of the obtained data; removing missing or slightly-changed indexes; carrying out data binning; screening a severe pancreatitis data prediction model; pre-training the selected model; screening and determining characteristic indexes associated with 10 severe pancreatitis according to a pre-training result, and training again; according to the working characteristic curve of the subject, a threshold value suitable for a prediction algorithm is determined, and then a final severe pancreatitis data prediction model is obtained. The non-invasive severe pancreatitis diagnosis model based on multiple clinical indexes solves the problem of diagnosis lag, is high in prediction speed and high in accuracy, and can provide reference for clinical diagnosis of severe pancreatitis.

The invention provides a method for preparing a pancreatic single cell suspension of chronic pancreatitis mouse. The method comprises the following steps: A chronic pancreatitis mice model builing; B, chronic pancreatitis mice pancreatic tissue sampling; C, pancreatic tissue collagenase digestion: a mixture of type I and type V collagenase is prepared by using a high glucose DMEM medium, and the collagenase mixture solution is preheated at 37 DEG C before treatment; the pancreatic tissue obtained in step B is transferred to the pre-warmed collagenase mixture, the materials are mixed fully, digested at 37 DEG C for 30 to 90 min, and mixed thoroughly every 10 min; and D, pancreatic single cell separation: the material is filtered once with a 70 [mu]m filter, the residue is discard, the cell suspension is centrifuged, a supernatant is discard, and resuspend deposition is carried out in high glucose DMEM medium; a 30 [mu]m filter is used for refiltering again, the residue is discarded, the cell suspension is centrifuged, and the supernatant and the upper cell debris, a DNA flocculent twister and a middle layer of blood cells are discarded, the white parenchymal cells at a lowermost layer are retained, and a PBS solution is resuspended to obtain the pancreatic single cell suspension of chronic pancreatitis mouse.

The invention provides application of Prussian blue in preparation of medicines for treating acute pancreatitis and a preparation method of Prussian blue nano-particles. Currently, no specific medicine against acute pancreatitis exists, so that a specific medicine for preventing and treating acute pancreatitis has certain practical significance.

The invention discloses a Chinese herbal medicine for treating acute pancreatitis. The Chinese herbal medicine is prepared from the following medicines in parts by weight: 25-35 parts of radix bupleuri, 25-35 parts of bitter orange, 15-25 parts of radix paeoniae rubra, 25-35 parts of rhizoma cyperi, 25-35 parts of the rhizome of chuanxiong, 25-35 parts of radix curcumae, 25-35 parts of rhizoma corydalis, 25-35 parts of salvia, 15-25 parts of dandelion, 15-25 parts of herba scutellariae barbatae, 35-45 parts of amur ampelopsis stem, 15-25 parts of coptis root, 15-25 parts of herba patriniae and 25-35 parts of sticktight. The Chinese herbal medicine is prepared by adding 1600 parts by weight of water, after the water is boiled, decocting the medicines with slow fire for 20-30 minutes, filtering the decoction and collecting the supernatant, decocting the supernatant three times, bottling and uniformly mixing the supernatant decocted three times and then sterilizing the supernatant under a high temperature for later use. Radix bupleuri is taken as the monarch, bitter orange and radix paeoniae rubra are taken as the ministers, rhizoma cyperi, the rhizome of chuanxiong, radix curcumae and rhizoma corydalis are taken as the assistants, and salvia, dandelion, herba scutellariae barbatae, amur ampelopsis stem, coptis root, herba patriniae and sticktight are taken as the guides.

The invention discloses a method for processing seed melon condensed juice, which comprises the following steps: (1), peeling and removing seeds; (2), squeezing to obtain juice; (3), treating with enzyme; (4), extinguishing enzyme; (5), carrying out centrifugal separation; (6), filtering; (7), concentrating; and (8), sterilizing. Seed melon condensed juice prepared according to the method tastes good, is delicious in flavor, low in sugar and rich in natural high-quality protein, vitamin, mineral matters and trace elements, and has the characteristics of quenching thirst, preventing alcoholism, appetizing and reducing heat; and long-term drinking of seed melon condensed juice has health-care and curing effects for diseases such as diabetes, hypertension, hyperlipemia, nephritis and pancreatitis.

The invention provides acute pancreatitis prognostic markers, an acute pancreatitis prognostic prediction model and application of the prediction model. The markers comprise any one or a combination of at least two of hsa-miR-4265, hsa-miR-1208, hsa-miR-516a or hsa-miR-3127. The hsa-miR-4265, the hsa-miR-1208, the hsa-miR-516a and the hsa-miR-3127 disclosed by the invention have obvious correlation with the acute pancreatitis with the continuous organ failure. According to the relative expression quantity of the markers, the acute pancreatitis prognosis prediction model can be constructed, whether a patient suffering from acute pancreatitis suffers from continuous organ failure or not is predicted in an individualized mode, and accurate and useful prognosis information is provided for thepatient suffering from acute pancreatitis.